Globenewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

StoneX Expands Wealth Management Offering for Latin American Clients

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

TCM Group A/S: Storaktionærmeddelelse

TCM Group A/S: Major shareholder announcement

NeuralTrust spots first signs of “self-fixing” AI in the wild

CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Intesa Sanpaolo's IMI Corporate & Investment Banking Division strengthens US role supporting transactions worth $50 billion in three years

Dolphin Liberty 600 by Maytronics Named to TIME’s List of the Best Inventions of 2025

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

WillScot Closes Amended and Extended Asset-Based Revolving Credit Facility

Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease

CrossAmerica Partners to Announce Third Quarter 2025 Earnings Results on November 5

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML